Literature DB >> 7286032

Pharmacokinetics of amiodarone after intravenous and oral administration.

F Andreasen, H Agerbaek, P Bjerregaard, H Gøtzsche.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7286032     DOI： 10.1007/BF00562807

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  11 in total

1.  [Myxedema caused by amiodarone; a further case].

Authors:  A Grand
Journal:  Coeur Med Interne       Date:  1975 Jan-Mar

Review 2.  New antiarrhythmic agents: amiodarone, aprindine, disopyramide, ethmozin, mexiletine, tocainide, verapamil.

Authors:  D P Zipes; P J Troup
Journal:  Am J Cardiol       Date:  1978-05-22       Impact factor: 2.778

3.  Hyperthyroidism as a possible complication of the treatment of ischemic heart disease with amiodarone.

Authors:  M H Jonckheer; P Blockx; R Kaivers; G Wyffels
Journal:  Acta Cardiol       Date:  1973       Impact factor: 1.718

4.  [Research on the benzofuran series. XXXVII. Comparative study of transit and metabolism of amiodarone in different species of animals and humans].

Authors:  J Broekhuysen; R Laruel; R Sion
Journal:  Arch Int Pharmacodyn Ther       Date:  1969-02

5.  Control of tachyarrhythmias associated with Wolff-Parkinson-White syndrome by amiodarone hydrochloride.

Authors:  M B Rosenbaum; P A Chiale; D Ryba; M V Elizari
Journal:  Am J Cardiol       Date:  1974-08       Impact factor: 2.778

6.  [Studies of the benzofuran series. XXV. Hemodynamic effects of amiodarone in the dog].

Authors:  R Charlier; A Baudine; F Chaillet; G Deltour
Journal:  Acta Cardiol       Date:  1967       Impact factor: 1.718

7.  Amiodarone pigmentation. An electron microscopic study.

Authors:  M L Geerts
Journal:  Arch Belg Dermatol Syphiligr       Date:  1971 Oct-Dec

8.  [Amiodarone and cutaneous depostis. Clinical and histological study].

Authors:  J Wanet; G Achten; G Barchewitz; C Mestdagh; M Vastesaeger
Journal:  Ann Dermatol Syphiligr (Paris)       Date:  1971

9.  Rapid high-performance liquid chromatographic method for the measurement of amiodarone in blood plasma or serum at the concentrations attained during therapy.

Authors:  R J Flanagan; G C Storey; D W Holt
Journal:  J Chromatogr       Date:  1980-01-18

10.  Clinical efficacy of amiodarone as an antiarrhythmic agent.

Authors:  M B Rosenbaum; P A Chiale; M S Halpern; G J Nau; J Przybylski; R J Levi; J O Lázzari; M V Elizari
Journal:  Am J Cardiol       Date:  1976-12       Impact factor: 2.778
View more
  27 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Recent advances in understanding the pharmacology of amiodarone.

Authors:  S Nattel; M Talajic
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

3.  In vitro amiodarone protein binding and its interaction with warfarin.

Authors:  P Neyroz; M Bonati
Journal:  Experientia       Date:  1985-03-15

4.  Bioavailability of drugs with long elimination half-lives.

Authors:  R Urso; L Aarons
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 5.  Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.

Authors:  Ahmed M A Adlan; Gregory Y H Lip
Journal:  Drug Saf       Date:  2013-02       Impact factor: 5.606

Review 6.  Clinical pharmacokinetics of amiodarone.

Authors:  R Latini; G Tognoni; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

7.  Alterations to the electrical activity of atrial muscle isolated from the rat heart, produced by exposure in vitro to amiodarone.

Authors:  B J Northover
Journal:  Br J Pharmacol       Date:  1984-05       Impact factor: 8.739

Review 8.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

Review 9.  Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia.

Authors:  Hugo Van Herendael; Paul Dorian
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

10.  Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method.

Authors:  M E Veronese; S McLean; R Hendriks
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.